JBC INTERFERin siRNA transfection reagent

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M304728200 on May 30, 2003

J. Biol. Chem., Vol. 278, Issue 32, 29693-29700, August 8, 2003
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
278/32/29693    most recent
M304728200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gong, P.
Right arrow Articles by Nieto, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gong, P.
Right arrow Articles by Nieto, N.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Increased Expression of Cytochrome P450 2E1 Induces Heme Oxygenase-1 through ERK MAPK Pathway*

Pengfei Gong, Arthur I. Cederbaum {ddagger} and Natalia Nieto

From the Department of Pharmacology and Biological Chemistry, Mount Sinai School of Medicine, New York, New York 10029

Received for publication, May 6, 2003 , and in revised form, May 23, 2003.


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The inducible form of heme oxygenase (HO-1) is increased during oxidative injury, and this may be an important defense mechanism against such injury. Cytochrome P450 2E1 (CYP2E1) generates reactive oxygen species and promotes lipid peroxidation. In this study induction of HO-1 by CYP2E1 and the possible role of mitogen-activated protein kinase (MAPK) in this process were evaluated. HO-1 induction was observed in the livers of chronic alcohol-fed mice or pyrazole-treated rats, conditions known to elevate CYP2E1 levels. Increased levels of HO-1 were observed in HepG2 cells overexpressing CYP2E1 (E47 cells) compared with control HepG2 cells or HepG2 cells expressing CYP3A4. Expression of CYP2E1 in HepG2 cells transcriptionally activated the HO-1 gene, increasing HO-1 mRNA and protein expression and activity of a HO-1 reporter construct. CYP2E1 inhibitors and catalase blocked the increased production of reactive oxygen species as well as HO-1 induction. Increasing oxidative stress by the addition of arachidonic acid or depletion of glutathione further increased HO-1 induction. The phosphorylated form of ERK MAPK but not that of p38 or JNK MAPK was increased in E47 cells compared with the control C34 HepG2 cells. PD98059, a specific inhibitor of ERK MAPK, blocked the activity of a HO-1 reporter in E47 cells but not in C34 cells. These results suggest that increased CYP2E1 activity leads to induction of the HO-1 gene, and the ERK MAPK pathway is important in mediating this process. This induction may serve as an adaptive mechanism to protect the E47 cells against the CYP2E1-dependent oxidative stress.


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Heme oxygenase (HO)1 is the rate-limiting enzyme in the conversion of heme into biliverdin, carbon monoxide (CO), and free iron (Fe2+) (1). Three HO isoforms have been identified; they are inducible HO-1, also known as heat shock protein 32, constitutively expressed HO-2, and a related but less well characterized HO-3 (2). Under physiologic conditions, HO-2 is the major HO isoform found in mammalian tissues, particularly in brain and testis (3). In contrast, HO-1 expression is relatively low, with the exception of the spleen, in which HO-1 levels are constitutively high. Up-regulation of HO-1 may be among the most critical cytoprotective mechanisms that are activated during cellular stress, such as inflammation, ischemia, hypoxia, hyperoxia, hyperthermia, or radiation (1), and thus, is thought to play a key role in maintaining antioxidant and oxidant homeostasis when cellular injury occurs (24). HO-1 expression is primarily regulated at the transcriptional level, although there are interspecies variations in the regulation of HO-1 (58).

The mitogen-activated protein kinases (MAPKs) are components of signaling cascades that respond to extracellular stimuli by targeting transcription factors, resulting in the modulation of gene expression. Three major MAP kinase subfamilies have been described; they are extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase, and p38. ERK was the first cascade to be elucidated; it is activated by mitogens and is primarily involved in the regulation of cell growth and proliferation. The remaining two cascades respond to cellular stress signals and are, hence, sometimes referred to as stress-activated protein kinases. There is a good deal of overlap among the cascades both in their targets and upstream activators. The signal transduction pathways that regulate HO-1 gene activation under the multiplicity of inducing conditions remain only partially understood. ERK and/or p38 MAPK have been reported to participate in the activation of the HO-1 gene by inducing xenobiotics (910).

Cytochrome P450 2E1 (CYP2E1), the ethanol-inducible form, metabolizes and activates many toxicologically important substrates including ethanol, carbon tetrachloride, acetaminophen, and N-nitrosodimethylamine to more toxic products (1113). Induction of CYP2E1 by ethanol is one of the central pathways by which ethanol generates a state of oxidative stress in hepatocytes. To study the biochemical and toxicological effects of CYP2E1 induction, our laboratory established a HepG2 cell line that constitutively overexpresses CYP2E1 (E47 cells) or a control HepG2 cell line transfected with the empty vector (C34 cells) (14). CYP2E1-dependent toxicity in the presence of ethanol, arachidonic acid (AA), and AA plus iron has been characterized in these cell lines; these agents did not produce significant toxicity in C34 cells, whereas their addition to E47 cells decreased cell viability and caused either necrosis or apoptosis (1417). Toxicity by these agents was enhanced when cellular glutathione (GSH) levels were lowered by treatment with L-buthionine-(S,R)-sulfoximine (BSO). Moreover, treatment of E47 cells with only BSO, an irreversible inhibitor of glutamate-cysteine ligase, resulted in apoptosis and necrosis (18), whereas no toxicity was found in C34 cells or HepG2 cells that expressed CYP3A4 instead of CYP2E1. Antioxidants such as GSH-ethyl ester and N-acetylcysteine partially prevented the apoptosis and necrosis after BSO treatment, whereas diallyl sulfide, a CYP2E1 inhibitor, was fully protective.

In response to the increased oxidative stress caused by induction of CYP2E1 activity in hepatocytes, antioxidant enzymes such as glutamate-cysteine ligase, catalase, and glutathione S-transferase were found to be up-regulated (1920). In this study, we present data showing that HO-1 is transcriptionally activated in HepG2 cells overexpressing CYP2E1 and that the ERK MAPK pathway plays an important role in mediating this activation.


    MATERIALS AND METHODS
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Animal Models—Male CD-1 mice (30 ~ 40 g) and male Sprague-Dawley rats (150 ~ 170 g) were housed in a facility approved by The American Association for Accreditation of Laboratory Animal Care. Mice were fed with commercially available ethanol (35%) and control diets (Bio-Serv, Frenchtown, NJ), which were equicaloric and had the same composition with respect to fat (42% of calories) and protein (16% of calories) for 59 days. To induce liver CYP2E1, rats were injected intraperitoneally with pyrazole, 200 mg/kg body weight, once per day for 2 days followed by overnight fast (21).

Cell Culture and Transfection Experiments—This study was performed using HepG2 cells, which constitutively express CYP2E1 (E47 cells) or control HepG2 cells (C34 cells), which have undetectable P450 activity (14). Cells were cultured in minimal essential medium containing 10% fetal bovine serum and 0.5 mg/ml of G418 supplemented with 100 units/ml of penicillin and 100 µg/ml of streptomycin and 2 mM L-glutamine in a humidified atmosphere in 5% CO2 at 37 °C. The expression of CYP2E1 was routinely monitored by assaying for the rate of oxidation of p-nitrophenol as described below. For each experiment, cells were plated and incubated in minimal essential medium overnight, the culture medium was replaced with fresh medium, and the different treatments were added. Plasmid pHHO-1 containing human HO-1 cDNA and pHHOSV15luc containing a 15-kilobase upstream promoter region of human HO-1 gene linked to a luciferase reporter gene were generous gifts from Dr. S. Shibahara (Tohoku University School of Medicine, Sendai, Japan). The CYP2E1 containing plasmid (pCI-2E1) and the empty vector pCI-neo have been previously described (22). The pRL-null plasmid was from Promega (Madison, WI). Transfections were carried out using FuGENE 6 (Roche Applied Science) as the DNA carrier.

General Methodology—CYP2E1 activity in microsomes (23) was measured by studying the oxidation of p-nitrophenol to p-nitrocatechol as described previously. HO activity was determined by detecting bilirubin production from heme oxidation by isolated microsomes (24). ROS was determined by flow cytometry with 2',7'-dichlorofluorescin-diacetate (25). Luciferase activity was determined using the dual luciferase reporter assay system (Promega).

Western Blotting—HO-1, HO-2, and CYP2E1 protein expression were detected by Western blotting as described previously (26). Each sample containing 30 µg of total protein was loaded on a 12% denaturing polyacrylamide gel and electroblotted onto 0.2-µm nitrocellulose membranes. Protein concentration was determined using the Protein DC-20 assay kit (Bio-Rad). Protein immunoblot analysis was carried out using the following: anti-human HO-1 (1:5000) and anti-rat HO-1 (1:5000) monoclonal antibody, anti-human HO-2 polyclonal antibody (1:2000) (StressGen Biotech, Victoria, BC, Canada); anti-human CYP2E1 polyclonal antibody (1:30,000) (kindly provided by Dr. J. M. Lasker, Hackensack Biomedical Research Institute, NJ); ERK, p38, c-Jun N-terminal kinase rat polyclonal antibody (1:1000) or phosphorylated ERK, p38, and c-Jun N-terminal kinase mouse monoclonal antibody (1:500) (Santa Cruz Biotechnology, Santa Cruz, CA) as primary antibody; horseradish peroxidase-conjugated goat anti-mouse IgG (1:4000) or goat anti-rabbit IgG (1:10,000) (Sigma) as secondary antibody. Blots were developed using the enhanced chemiluminescence immunoblot-detecting reagent (Amersham Biosciences).

Northern Blotting—Total RNA was isolated using the TRIzol reagent (Invitrogen). 5 µg of RNA were electrophoresed under denaturing conditions in 0.9% agarose/formaldehyde gels, transferred onto nylon membranes, and hybridized to random-primed 32P-labeled HO-1 or ribosomal S3 cDNA probes as described previously (27). HO-1 cDNA was produced by digesting the plasmid pHHO1 with XhoI and XbaI.

Statistics—Data are presented as average ± S.E. (n = 3). Student's t test for unpaired data was used to evaluate the differences between the compared groups.


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
HO-1 Protein Expression Is Induced in Liver of Mice Chronically Fed Ethanol—Although CYP2E1 is induced by ethanol, little is known about changes of HO-1 expression if any in the liver of animals treated with ethanol. In this study, male CD-1 mice (30 ~ 40 g) were fed with a control diet or a diet containing 35% ethanol for 59 days. CYP2E1 and HO-1 protein expression in liver was detected by Western blotting. CYP2E1 protein was significantly increased in mice fed ethanol compared with control mice (4-fold, p < 0.001). Although HO-1 protein could not be detected in the liver of control mice, it was detectable in mice fed ethanol (Fig. 1A).



View larger version (17K):
[in this window]
[in a new window]
 
FIG. 1.
HO-1 protein is increased in livers of mice chronically fed with ethanol and rats injected with pyrazole. A, male CD-1 mice (30 ~ 40 g) were fed with a control diet or a diet containing ethanol (up to 35%) for 59 days. B, rats were treated with 0.9% NaCl or with pyrazole (200 mg/kg, 2 days) as described under "Materials and Methods." HO-1 and CYP2E1 proteins in liver homogenates were detected by Western blotting. Results are expressed as arbitrary densitometric units under the blots and represent average ± S.E. (n = 3). ***, p < 0.001 versus corresponding control groups. The HO-1 protein band in A is not quantified because it is undetectable in the control mice.

 

Induction of CYP2E1 in Vivo by Pyrazole Increases HO-1 Protein Expression in Rat Liver—Pyrazole induces CYP2E1 by stabilizing the protein against degradation. Increased CYP2E1 activity results in increased oxidative stress (16, 28). To evaluate whether there were any changes in HO-1 levels by the increased CYP2E1 activity in hepatocytes, rats were treated with 0.9% NaCl (control) or pyrazole (200 mg/kg of body weight/day for 2 days followed by an overnight fast). After sacrificing the rats, the livers were removed, and CYP2E1 and HO-1 content were determined by Western blotting. CYP2E1 protein was increased about 5.6-fold, whereas HO-1 protein was induced about 3.2-fold in the liver of pyrazole-treated rats compared with the saline-treated rats (Fig. 1B).

Overexpression of CYP2E1 in HepG2 Cells Induces HO-1 Protein and HO Activity—To determine whether there is any link between the induction of CYP2E1 and HO-1 levels, HepG2 cells stably transfected with CYP2E1 (E47 cells) or with the empty vector (C34 cells) were used. HepG2 cells transfected with CYP3A4 (3A4 cells), another isoform of the cytochrome P450 family, were also studied as a parallel control. HO-2, the constitutive isoform of HO, was unchanged by expression of either CYP2E1 or CYP3A4 (Fig. 2A). HO-1 protein and HO activity were low in the control C34 and 3A4 cells (Fig. 2, A and B), which have undetectable CYP2E1 protein levels (Fig. 2A) and very low basal CYP2E1 activity (Fig. 2C). However, HO-1 protein and HO activity were increased (about 2.2- and 2.1-fold, respectively) in E47 cells (Fig. 2, A and B), which have high levels of CYP2E1 protein (Fig. 2A) and high CYP2E1 activity (Fig. 2C), suggesting a potential association between increased CYP2E1 expression and induction of HO-1 protein and activity in HepG2 cells.



View larger version (19K):
[in this window]
[in a new window]
 
FIG. 2.
HO-1 protein and HO activity are increased in E47 cells. Control HepG2 (C34) cells or HepG2 cells expressing CYP2E1 (E47) or CYP3A4 (3A4) cells were incubated overnight and HO-1, HO-2, and CYP2E1 proteins in the cell lysates were detected by Western blotting. Results are expressed as arbitrary densitometric units under the blots and represent average ± S.E. (n = 3). **, p < 0.01 versus control C34 cells (A). HO activity (pmol of bilirubin/min/mg of protein) (B), and microsome CYP2E1 activity (pmol p-nitrocatechol/min/mg of protein (C) were measured as described under "Materials and Methods." Data are expressed as the average ± S.E. (n = 3). ***, p < 0.001 versus C34 cells.

 

HO-1 Gene Is Transcriptionally Activated by CYP2E1-Overexpression—Because HO-1 protein was increased in HepG2 cells overexpressing CYP2E1, we examined whether such an increase was also present at the mRNA level. HO-1 mRNA was increased about 2-fold in E47 cells but not in 3A4 cells when compared with the control C34 cells (Fig. 3A), suggesting the possibility that CYP2E1 overexpression affects HO-1 gene expression at the transcription level. Increased mRNA levels may be because of an increase in transcription or to an increase in stability. To study whether this increase of HO-1 mRNA involves changes in mRNA stability, actinomycin D (10 µg/ml), a general inhibitor of mRNA transcription, was used to block HO-1 gene transcription, and the decline in the remaining HO-1 mRNA levels was followed as a function of time after the addition of actinomycin D. As shown in Fig. 3, B–C, the degradation rate of HO-1 mRNA in E47 cells was similar to that in C34 cells (p > 0.05 at all time points, half-life about 8 h), suggesting that increased HO-1 mRNA expression in E47 cells is not due to increased stability of the HO-1 mRNA. Transient transfection studies were carried out with a HO-1 promoter construct (pHHO15SVluc) that contained the 15-kilobase upstream region of the human HO-1 gene (29). Luciferase activity in E47 cells transfected with pHHO15SVluc was 1.8-fold higher (p < 0.05) than that in control C34 cells transfected with the same construct (Fig. 4A), an increase similar to the HO-1 mRNA levels (Fig. 3A). To rule out changes in clonal selection as an explanation for the increase in HO-1, the C34 cells were transfected with CYP2E1. Luciferase activity of C34 cells co-transfected with CYP2E1 (pCI-2E1) and pHHO15SVluc was 3.4-fold higher than that of C34 cells co-transfected with the empty vector pCI-neo and pHHO15SVluc (Fig. 4B), validating that CYP2E1 expression enhances HO-1 expression. Taken together, these data suggest that the HO-1 gene is transcriptionally activated by overexpression of CYP2E1 in HepG2 cells.



View larger version (25K):
[in this window]
[in a new window]
 
FIG. 3.
HO-1 mRNA expression and stability in E47 cells. A, C34, 3A4, and E47 cells were incubated overnight, and HO-1 and S3 mRNAs were detected by Northern blotting. The amount of HO-1 mRNA was normalized to S3 mRNA, and the ratios of HO-1/S3 mRNA are expressed as arbitrary densitometric units under the blots and represent the average ± S.E. (n = 3). **, p < 0.01 versus C34 cells. B, C34 or E47 cells were treated with 10 µg/ml actinomycin D for 0, 8, 24, and 48 h. HO-1 mRNA was detected by Northern blotting. C, HO-1 mRNA was quantified, and the amount of HO-1 mRNA at 0 h was assigned a value of 100%. Data are expressed as the average ± S.E. (n = 3). p > 0.05 at all time points.

 


View larger version (11K):
[in this window]
[in a new window]
 
FIG. 4.
Overexpression of CYP2E1 increases HO-1 reporter activity. A, C34 or E47 cells were co-transfected with pHHO15SVluc (1 µg) and pRL-null (50 ng) for 24 h. B, C34 cells were co-transfected with pHHO15SVluc (1 µg) plus pCI-2E1 or pHHO15SVluc (1 µg) plus pCI-neo (1 µg) and pRL-null (50 ng) for 24 h. Luciferase activity was determined using the dual luciferase reporter assay system. The firefly luciferase activity was normalized to that of the Renilla luciferase activity. Normalized luciferase activities were expressed as fold induction compared with that of the C34 cells. Data are expressed as the average ± S.E. (n = 3). **, p < 0.01 versus control C34 cells (A) or C34 cells transfected with pCI-neo (B).

 

Inhibitors of CYP2E1 Activity Prevent the Increase of ROS Production as Well as HO-1 Induction in E47 Cells—Increased CYP2E1 activity has been shown to increase ROS production (16, 28). To examine whether the induction of HO-1 in E47 cells was caused by an increase in ROS production, the effect of CYP2E1 inhibitors such as diallyl sulfide (DAS) (30), 4-methylpyrazole (4-MP) (31), and dimethyl sulfoxide (Me2SO) (32) on HO-1 induction was determined. ROS production was assayed by 2',7'-dichlorofluorescin fluorescence. E47 cells showed an elevated basal ROS production (1.8-fold, p < 0.05) compared with control C34 cells (Fig. 5A). Incubation with 1 mM DAS, 5 mM 4-MP, or 211 mM Me2SO for 3 days significantly inhibited the increase in ROS production in E47 cells (from 1.8-fold to 1.2-, 1.1-, and 0.7-fold, respectively), whereas these compounds did not significantly affect ROS production in C34 cells (p > 0.05) (Fig. 5A).



View larger version (22K):
[in this window]
[in a new window]
 
FIG. 5.
Inhibitors of CYP2E1 decrease ROS production as well as HO-1 mRNA induction in E47 cells. Cells were untreated (control (C)) or treated with 1 mM DAS, 5 mM 4-MP, or 211 mM Me2SO (DMSO) for 3 days. ROS production was determined by flow cytometry with 2',7'-dichlorofluorescin-diacetate, and the results were expressed as fold induction compared with the corresponding untreated cells. The amount of ROS in untreated C34 cells was assigned a value of 1 (A). HO-1 and S3 mRNA in samples from the above experiment were detected by Northern blotting (B). The hybridization bands were quantified. The amount of HO-1 mRNA was normalized to that of S3 mRNA, and the results were expressed as fold induction compared with control C34 cells, which were assigned a value of 1 (C). Data are expressed as the average ± S.E. (n = 3). **, p < 0.01 versus control C34 cells. ##, p < 0.01 versus control E47 cells.

 

In a similar manner to the inhibition of CYP2E1 activity and decrease in ROS production, HO-1 induction in E47 cells was also prevented by these inhibitors. Incubation of E47 cells with 1 mM DAS, 5 mM 4-MP, or 211 mM Me2SO for 3 days significantly inhibited the HO-1 mRNA induction in E47 cells (from 2.2-fold to 1.2-, 0.8-, and 0.7-fold, respectively) when compared with control C34 cells (Fig. 5, B–C). E47 cells also had an elevated HO-1 protein level (about 3-fold) compared with control C34 cells in the absence of any addition (Fig. 6, A–B). This induction of HO-1 protein was also prevented by DAS, 4-MP, or Me2SO (from 3.2-fold to 1.58-, 0.65-, and 0.70-fold, respectively) compared with control C34 cells. These three inhibitors did not show significant effects on HO-1 protein expression in C34 cells (Fig. 6, A–B), validating their specificity for effects on CYP2E1.



View larger version (17K):
[in this window]
[in a new window]
 
FIG. 6.
HO-1 protein induction in E47 cells is blocked by inhibitors of CYP2E1. Cells were untreated (labeled as C) or treated with 1 mM DAS, 5 mM 4-MP, or 211 mM Me2SO (DMSO) for 3 days. HO-1 protein was detected by Western blot (A). The protein bands were quantified and expressed as fold induction compared with that of the untreated C34 cells, which was assigned a value of 1 (B). Data are expressed as the average ± S.E. (n = 3). ***, p < 0.001 versus untreated C34 cells. ##, p < 0.01, and ###, p < 0.001 versus untreated E47 cells.

 

Catalase Inhibits the Induction of HO-1 by CYP2E1 Overexpression—Increased CYP2E1 activity by overexpressing CYP2E1 increases production of ROS such as H2O2, , and lipid peroxidation end products (14, 32). Catalase effectively decomposes hydrogen peroxide, whereas vitamin E, the principal lipid-soluble antioxidant in biological tissues, is widely used to prevent the onset of cell damage due to the induction of lipid peroxidation (33). To further characterize the role of ROS in the mechanism of HO-1 induction by CYP2E1, 5000 units/ml catalase or 100 µM vitamin E were added to the culture medium for 48 h. Both the increases in HO-1 mRNA and protein in E47 cells were almost completely inhibited by catalase (93 and 89%, respectively), whereas vitamin E had no effect (Fig. 7, A–B), suggesting a potential role for hydrogen peroxide in the induction of the HO-1 gene by CYP2E1 overexpression.



View larger version (32K):
[in this window]
[in a new window]
 
FIG. 7.
HO-1 mRNA and protein induction in E47 cells is blocked by catalase. Cells were incubated in the presence or absence of 5000 units/ml catalase (Cat) or 100 µM vitamin E (VitE) for 24 h. HO-1 and S3 mRNA were detected by Northern blotting. The amount of HO-1 mRNA was normalized to S3 mRNA, and the results were expressed as fold induction compared with that of untreated C34 cells, which was assigned a value of 1 (A). HO-1 and CYP2E1 proteins were detected by Western blotting and quantified. The arbitrary densitometric units of untreated C34 cells was assigned a value of 1 (B). Data expressed under the blotting bands are the average ± S.E. (n = 3). *, p < 0.05 versus untreated E47 cells.

 

ERK MAPK Is Activated by Overexpression of CYP2E1—To determine the role, if any, of MAPKs in HO-1 gene activation by overexpression of CYP2E1, we first examined the effect of overexpression of CYP2E1 on MAPK activities. MAPKs are activated by dual phosphorylation of threonine and tyrosine residues located in the "activation lip" of the conserved core kinase sequence (34), and the activated species can be detected by antibodies directed against phosphorylated peptides encompassing these residues. Untreated C34 or E47 cells were incubated overnight, and cell extracts were analyzed for phosphorylated and total MAPKs by Western blotting. Although the phosphorylated form of all three MAPKs (ERK, p38, c-Jun N-terminal kinase) can be detected in both C34 and E47 cells, only the phosphorylated ERK was increased in E47 cells compared with C34 cells (Fig. 8, A–B), suggesting that ERK MAPK is activated by overexpression of CYP2E1. The increase in the levels of phosphorylated ERK was not due to a concomitant elevation in the amount of ERK since the level of ERK (ERK1 or ERK2) in E47 cells was unchanged compared with C34 cells (Fig. 8, A–B), suggesting that ERK MAPK is activated by overexpression of CYP2E1.



View larger version (28K):
[in this window]
[in a new window]
 
FIG. 8.
ERK MAPK is activated and important for the activation of HO-1 reporter gene in E47 cells. A and B, ERK MAPK is activated in E47 cells. C34 and E47 cells were incubated overnight and ERK, phosphorylated ERK (P-ERK), p38, phosphorylated p38 (P-p38), c-Jun N-terminal kinase (JNK), and phosphorylated c-Jun N-terminal kinase (P-JNK) proteins were detected by Western blotting (A). The quantified results were expressed as fold induction compared with C34 cells. n = 3, **, p < 0.01 versus C34 cells (B). C, MAPK inhibitor PD98059 selectively inhibited HO-1 promoter-reporter gene activity in E47 cells. C34 or E47 cells were co-transfected with the HO-1 reporter (pHHO15SVluc, 1 µg) and pRL-null (50 ng) for 24 h. After a change of medium, the cells were further incubated with 10 µM of PD98059 (PD), 10 µM SB203580 (SB), or 10 µM wortmannin (W) for 6 h. Luciferase activity was determined using the dual luciferase reporter assay system. pHHO15SVluc activity was normalized to pRL-null activity, and the arbitrary densitometric units of untreated C34 cells were assigned a value of 100%. Data were expressed as average ± S.E., n = 3. **, p < 0.01 versus untreated C34 cells. ##, p < 0.01, and ###, p < 0.001 versus untreated E47 cells.

 

ERK MAPK Pathway Is Important for the Induction of HO-1 by Overexpression of CYP2E1—To address the role of individual MAPK pathways in HO-1 gene activation by overexpression of CYP2E1, we examined the effects of PD98059, an ERK pathway inhibitor, and SB203580, an inhibitor of p38, on pHHOSV15luc expression. The effect of wortmannin, an inhibitor of the phosphatidylinositol 3-kinase pathway, on pHHOSV15luc expression was also studied. C34 and E47 cells were transfected with the HO-1 reporter gene construct (pHHO15SVluc) and then treated with 10 µM SB203580, 10 µM PD98059 (Calbiochem), or 10 µM Wortmannin (Sigma) for 6 h. Luciferase activity was determined using the dual luciferase reporter assay system. Consistent with higher expression of HO-1 mRNA, E47 cells have about a 1.8-fold higher pHHO15SVluc activity than C34 cells (Fig. 8C). PD98059 blocked the increased HO-1 reporter activity in E47 cells (from 178 to 101%), whereas it did not have any effect on the reporter activity of C34 cells (from 100 to 101%) (Fig. 8C), suggesting that ERK MAPK plays an important role for the activation of HO-1 by overexpression of CYP2E1. SB203580 significantly and comparably attenuated HO-1 reporter activity in both C34 and E47 cells (from 100 and 178% to 41 and 45%, respectively) (Fig. 8C), suggesting that the p38 MAPK pathway may be important for the basal HO-1 expression in HepG2 cells. In contrast, the phosphatidylinositol 3-kinase inhibitor wortmannin did not have any effects on HO-1 reporter activity either in C34 or E47 cells (Fig. 8C), suggesting that this pathway is not important for HO-1 gene expression in HepG2 cells.

HO-1 mRNA and Protein Are further Induced after Treatment with AA and BSO in the E47 Cells—AA and BSO have been shown to increase oxidative stress and cause toxicity in E47 cells but not in C34 cells (14, 16, 18, 22). To evaluate the response of HO-1 to these CYP2E1-dependent pro-oxidants, E47 and C34 cells were incubated with or without 50 µM AA or 100 µM BSO for 48 h. Both HO-1 mRNA and protein were further elevated about 3-fold in the E47 cells after treatment with AA or BSO (Figs. 9A and 10A). HO-1 mRNA and protein were only slightly increased by AA or BSO in the C34 cells (1.6- and 1.2-fold, respectively) (Figs. 9B and 10B). HO-2 protein expression was not affected by AA or BSO treatment (Fig. 10, A–B). Because HO-1 induction is a good indicator of a response to oxidative stress, the further increases of HO-1 expression in E47 cells most likely reflect the increased oxidative stress generated by AA and BSO.



View larger version (33K):
[in this window]
[in a new window]
 
FIG. 9.
HO-1 mRNA expression is further induced by AA and BSO in E47 cells. E47 cells (A) and C34 cells (B) were untreated (control) or treated with 50 µM AA or 100 µM BSO for 48 h. HO-1 and S3 mRNA were detected by Northern blotting. The amount of HO-1 mRNA was normalized to S3 mRNA, and the results were expressed as fold induction compared with that of untreated cells. Data are expressed under the blotting bands as average ± S.E. (n = 3). *, p < 0.05, and **, p < 0.01 versus untreated control cells.

 


View larger version (40K):
[in this window]
[in a new window]
 
FIG. 10.
HO-1 protein expression is further induced by AA and BSO in E47 cells. E47 cells (A) and C34 cells (B) were untreated (control) or treated with 50 µM AA or 100 µM BSO for 48 h. HO-1, HO-2, and CYP2E1 proteins were detected by Western blotting. The protein bands were quantified and expressed as fold induction compared with that of untreated cells. Data are expressed under the blotting bands as average ± S.E. (n = 3). *, p < 0.05, and **, p < 0.01 versus untreated control cells.

 


    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Oxidative stress plays an important role in alcoholic injury (3536). However, little is known about changes of HO-1, an important antioxidant gene, in alcoholic liver disease. The present study shows that in chronic ethanol-fed mice, liver HO-1 protein expression is increased. This induction of HO-1 may be caused by induction of CYP2E1, although this remains to be studied. Chronic alcohol feeding of mice increases CYP2E1 expression, and induction of CYP2E1 is one of the central pathways by which ethanol generates a state of oxidative stress (28). Induction of CYP2E1 by injecting pyrazole to rats was found to induce HO-1 protein expression. In addition, HO-1 is induced in HepG2 cells overexpressing CYP2E1 but not in HepG2 cells overexpressing CYP3A4, another isoform of the P450 family. Increased expression of CYP2E1 induces HO-1; this conclusion is also supported by a recent study in which CYP2E1 was transfected into a human hepatoma cell line HLE (37).

In the present study we have used a HepG2 cell line that overexpresses CYP2E1 to determine the mechanism of induction of HO-1. CYP2E1, when reduced by NADPH-cytochrome P450 reductase, is a loosely coupled enzyme that displays high NADPH oxidase activity and is very reactive in catalysis of lipid peroxidation and production of ROS relative to other P450 isoforms (3839). Increased CYP2E1 activity is usually accompanied by increased ROS production and lipid peroxidation (14, 30). E47 cells were found to have increased HO-1 protein and mRNA expression as well as elevated HO activity. Up-regulation of HO-1 by CYP2E1 may be an adaptive response of cells to the increased oxidative stress caused by the increased CYP2E1 activity. Effective inhibitors of CYP2E1 activity, such as DAS, 4-MP, and Me2SO, which inhibited the increased ROS production in E47 cells, also inhibited HO-1 induction in these cells. Other antioxidant genes such as glutamate-cysteine ligase, catalase, and glutathione S-transferase are also up-regulated by overexpression of CYP2E1 (1920) and, like HO-1, may reflect adaptive responses to the overexpression of CYP2E1.

HO-1 is transcriptionally activated in HepG2 cells by overexpression of CYP2E1. E47 cells have increased HO-1 mRNA expression, whereas HO-1 mRNA degradation rates are unchanged compared with control HepG2 cells (C34 cells). Transfection of a human HO-1 promoter-reporter gene construct (pHHO15SVluc) into E47 and C34 cells further confirmed that the HO-1 promoter is activated by expression of CYP2E1. Hydrogen peroxide may possibly play a role in mediating this transactivation of the HO-1 gene by CYP2E1, since the addition of catalase, which decomposes hydrogen peroxide, blocked the induction of HO-1 mRNA and protein in E47 cells. It is not clear whether the added catalase is operating intracellularly or extracellularly; uptake of catalase by hepatocytes by an endocytosis-dependent mechanism has been reported (40). Alternatively, because hydrogen peroxide is diffusible, extracellular catalase may function as an extracellular sink, removing intracellular hydrogen peroxide down its concentration gradient (17, 25). Hydrogen peroxide has been reported to increase the DNA binding activity of the cadmium-response element on the promoter region of the human HO-1 gene (41) and activate HO-1 gene transcription in HepG2 cells (42). Increased CYP2E1 activity also increases lipid peroxidation in E47 cells (14). However, lipid peroxidation reactions do not appear to play an important role in explaining the up-regulation of the HO-1 gene in the untreated E47 cells, since the addition of the classical inhibitor of lipid peroxidation, vitamin E, does not prevent the induction of HO-1 protein and mRNA.

MAPK pathways, including ERK and/or p38 MAPK, have been reported to participate in the activation of the HO-1 gene by inducing xenobiotics (910). In this study we found that the ERK MAPK pathway possibly mediates the HO-1 gene activation by overexpression of CYP2E1 in HepG2 cells, whereas p38 MAPK is important for the basal HO-1 expression in HepG2 cells. ERK is activated by overexpression of CYP2E1 in HepG2 cells. Compared with the control C34 cells, E47 cells have higher levels of phosphorylated ERK, whereas the levels of phosphorylated p38 and c-Jun N-terminal kinase are not changed. Inhibition of the ERK MAPK pathway by PD98059 blocked the increase of a HO-1 reporter gene (pHHOSV15luc) activity in E47 cells but had no effect in the control C34 cells, providing a correlation between the HO-1 promoter activity and ERK MAPK pathway. Inhibition of the p38 MAPK pathway by the specific inhibitor SB203580 significantly attenuated the HO-1 reporter basal activity in the control HepG2 cells (C34 cells) as well as HO-1 reporter activity in E47 cells, suggesting an essential role of the p38 MAPK pathway in maintaining the basal activity of the HO-1 promoter and supporting subsequent response to HO-1 inducers in HepG2 cells. We hypothesize that CYP2E1-derived oxidative stress results in activation of the ERK MAPK pathway, which is then followed by increased transcription of the HO-1 gene by a signaling mechanism also dependent on p38 MAPK activity. Increased production of ROS by overexpression of CYP2E1 is likely the link between activation of ERK and the up-regulation of HO-1 expression.

As shown in previous studies (18, 22, 21), AA and BSO caused significant increases in ROS production and lipid peroxidation and toxicity in the E47 cells but had little effect in C34 cells. AA and BSO also significantly increased HO-1 mRNA and protein expression in the E47 cells in contrast to a slight increase in C34 cells. HO-1 induction is a good indicator of oxidative stress. Induction of HO-1 in E47 cells by AA and BSO may reflect the further increase in oxidative stress caused by AA and BSO over the basal stress generated by CYP2E1 expression, since AA and BSO significantly increase ROS production and lipid peroxidation in E47 cells. The functional significance of this induction of HO-1 is currently under investigation; preliminary studies show that inhibitors of HO-1 potentiate the CYP2E1 plus AA- or CYP2E1 plus BSO-dependent toxicities in E47 cells, in association with an increase in oxidative stress.2


    FOOTNOTES
 
* These studies were supported by The Revson Fellowship, a grant from the Alcoholic Beverage Medical Research Foundation, and a grant from the American Liver Foundation (to N. N.) and by United States Public Health Service, National Institute on Alcohol Abuse and Alcoholism Grant AA 03312 (to A. I. C.).The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

{ddagger} To whom correspondence should be addressed: Dept. of Pharmacology and Biological Chemistry, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029. Tel.: 212-241-7285; Fax: 212-996-7214; E-mail: arthur.cederbaum{at}mssm.edu.

1 The abbreviations used are: HO, heme oxygenase; AA, arachidonic acid; BSO, L-buthionine-(S,R)-sulfoximine; CYP2E1, cytochrome P450 2E1; C34 cells, HepG2 cell line established after transfection with pCI-neo; E47 cells, HepG2 cell line established after transfection with pCI-neo-CYP2E1; DAS, diallyl sulfide; ERK, extracellular signal-regulated kinase; MAPK, mitogen-activated protein kinase; ROS, reactive oxygen species; 4-MP, 4-methylpyrazole. Back

2 P. Gong, unpublished observations. Back


    ACKNOWLEDGMENTS
 
We thank Dr. Irina Kessova (Mount Sinai School of Medicine) for providing the samples of ethanol-fed mice.



    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Choi, A., and Alam, J. (1996) Am. J. Respir. Cell Mol. Biol. 15, 9–19[Abstract]
  2. Akagi, R., Takahashi, T., and Sassa, S. (2002) Jpn. J. Pharmacol. 88, 127–132[CrossRef][Medline] [Order article via Infotrieve]
  3. Maines, M. D. (1997) Annu. Rev. Pharmacol. Toxicol. 37, 517–585[CrossRef][Medline] [Order article via Infotrieve]
  4. Dennery, P. A. (2000) Curr. Top. Cell. Regul. 36, 181–199[Medline] [Order article via Infotrieve]
  5. Rizzardini, M., Terao, M., Falciani, F., and Cantoni, L. (1993) Biochem. J. 290, 343–347[Medline] [Order article via Infotrieve]
  6. Agarwal, A., Shiraishi, F., Visner, G. A., and Nick, H. S. (1998) J. Am. Soc. Nephrol. 9, 1990–1997[Abstract]
  7. Fogg, S., Agarwal, A., Nick, H. S., and Visner, G. A. (1999) Am. J. Respir. Cell Mol. Biol. 20, 797–804[Abstract/Free Full Text]
  8. Durante, W., Kroll, M. H., Christodoulides, N., Peyton, K. J., and Schafer, A. I. (1997) Circ. Res. 80, 557–564[Abstract/Free Full Text]
  9. Ryter, S. W., Otterbein, L. E., Morse, D., and Choi, A. M. (2002) Mol. Cell. Biochem. 234/235, 249–263
  10. Morse, D., and Choi, A. M. (2002) Am. J. Respir. Cell Mol. Biol. 27, 8–16[Abstract/Free Full Text]
  11. Guengerich, F. P., Kim, D. H., and Iwasaki, M. (1991) Chem. Res. Toxicol. 4, 168–179[CrossRef][Medline] [Order article via Infotrieve]
  12. Koop, D. R. (1992) FASEB J. 6, 724–730[Abstract]
  13. Yang, C. S., Yoo, J. S., Ishizaki, H., and Hong, J. Y. (1990) Drug Metab. Rev. 22, 147–159[Medline] [Order article via Infotrieve]
  14. Chen, Q., and Cederbaum, A. I. (1998) Mol. Pharmacol. 53, 638–648[Abstract/Free Full Text]
  15. Wu, D., and Cederbaum, A. I. (1996) J. Biol. Chem. 271, 23914–23919[Abstract/Free Full Text]
  16. Chen, Q., Galleano, M., and Cederbaum, A. I. (1997) J. Biol. Chem. 272, 14532–14541[Abstract/Free Full Text]
  17. Sakurai, K., and Cederbaum, A. I. (1998) Mol. Pharmacol. 54, 1024–1035[Abstract/Free Full Text]
  18. Wu, D., and Cederbaum, A. I. (2001) Alcohol Clin. Exp. Res. 25, 619–628[CrossRef][Medline] [Order article via Infotrieve]
  19. Mari, M., and Cederbaum, A. I. (2000) J. Biol. Chem. 275, 15563–15571[Abstract/Free Full Text]
  20. Mari, M., and Cederbaum, A. I. (2001) Hepatology 33, 652–661[CrossRef][Medline] [Order article via Infotrieve]
  21. Wu, D., and Cederbaum, A. I. (1993) J. Pharmacol. Exp. Ther. 264, 1468–1473[Abstract/Free Full Text]
  22. Nieto, N., Friedman, S. L., Greenwel, P., and Cederbaum, A. I. (1999) Hepatology 30, 987–996[CrossRef][Medline] [Order article via Infotrieve]
  23. Reinke, L. A., and Moyer, M. J. (1985) Drug Metab. Dispos. 13, 548–552[Abstract]
  24. Chen, J. X., Zeng, H., Chen, X., Su, C. Y., and Lai, C. C. (2001) Pharmacol. Res. 43, 63–69[CrossRef][Medline] [Order article via Infotrieve]
  25. Bai, J., Rodriguez, A. M., Melendez, J. A., and Cederbaum, A. I. (1999) J. Biol. Chem. 274, 26217–26224[Abstract/Free Full Text]
  26. Gong, P., Stewart, D., Hu, B., Li, N., Cook, J., Nel, A., and Alam, J. (2002) Antioxid. Redox Signal. 4, 249–257[CrossRef][Medline] [Order article via Infotrieve]
  27. Gong. P., Hu, B., Stewart, D., Ellerbe, M., Figueroa, Y. G., Blank, V., Beckman, B. S., and Alam, J. (2001) J. Biol. Chem. 276, 27018–27025[Abstract/Free Full Text]
  28. Cederbaum, A. I., Wu, D., Mari, M., and Bai, J. (2001) Free Radic. Biol. Med. 31, 1539–1543[CrossRef][Medline] [Order article via Infotrieve]
  29. Shibahara, S., Sato, M., Muller, R. M., and Yoshida, T. (1989) Eur. J. Biochem. 179, 557–563[Medline] [Order article via Infotrieve]
  30. Wu, C. C., Sheen, L. Y., Chen, H. W., Tsai, S. J., and Lii, C. K. (2001) Food Chem. Toxicol. 39, 563–569[CrossRef][Medline] [Order article via Infotrieve]
  31. Feierman, D. E., and Cederbaum, A. I. (1989) Chem. Res. Toxicol. 2, 359–366[CrossRef][Medline] [Order article via Infotrieve]
  32. Chen, Q., and Cederbaum, A. I. (1997) Curr. Topics Pharmacol. 3, 67–76
  33. Pratico, D., Iuliano, L., Basili, S., Ferro, D., Camastra, C., Cordova, C., FitzGerald, G. A., and Violi, F. (1998) J. Investig. Med. 46, 51–57[Medline] [Order article via Infotrieve]
  34. Lewis, T. S., Shapiro, P. S., and Ahn, A. G. (1998) Adv. Cancer Res. 74, 49–139[Medline] [Order article via Infotrieve]
  35. Nordmann, R., Riviere, C., and Rouach, H. (1992) Free Radic. Biol. Med. 12, 219–240[CrossRef][Medline] [Order article via Infotrieve]
  36. Tsukamoto, H., and Lu, S. C. (2001) FASEB J. 15, 1335–1349[Abstract/Free Full Text]
  37. Takahashi, S., Takahashi, T., Mizobuchi, S., Matsumi, M., Yokoyama, M., Morita, K., Miyazaki, M., Namba, M., Akagi, R., and Sassa, S. (2003) Int. J. Mol. Med. 11, 57–62[Medline] [Order article via Infotrieve]
  38. Gorsky, L. D., Koop, D. R., and Coon, M. J. (1984) J. Biol. Chem. 259, 6812–6817[Abstract/Free Full Text]
  39. Ekstrom, G., and Ingelman-Sundberg, M. (1989) Biochem. Pharmacol. 38, 1313–1319[CrossRef][Medline] [Order article via Infotrieve]
  40. Kyle, M. E., Nakae, D., Sakaida, I., Miccadei, S., and Farber, J. L. (1988) J. Biol. Chem. 263, 3784–3789[Abstract/Free Full Text]
  41. Favatier, F., and Polla, B. S. (2001) Biochem. J. 353, 475–482[CrossRef][Medline] [Order article via Infotrieve]
  42. Takahashi, S., Takahashi, Y., Yoshimi, T., and Miura, T. (1998) Cell Biochem. Funct. 16, 183–193[CrossRef][Medline] [Order article via Infotrieve]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Eur Respir JHome page
M-Y. Li, J. Yip, M. K. Y. Hsin, T. S. K. Mok, Y. Wu, M. J. Underwood, and G. G. Chen
Haem oxygenase-1 plays a central role in NNK-mediated lung carcinogenesis
Eur. Respir. J., October 1, 2008; 32(4): 911 - 923.
[Abstract] [Full Text] [PDF]


Home page
Toxicol PatholHome page
L. M. Aleksunes and J. E. Manautou
Emerging Role of Nrf2 in Protecting Against Hepatic and Gastrointestinal Disease
Toxicol Pathol, June 1, 2007; 35(4): 459 - 473.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Aburaya, K.-I. Tanaka, T. Hoshino, S. Tsutsumi, K. Suzuki, M. Makise, R. Akagi, and T. Mizushima
Heme Oxygenase-1 Protects Gastric Mucosal Cells against Non-steroidal Anti-inflammatory Drugs
J. Biol. Chem., November 3, 2006; 281(44): 33422 - 33432.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
Y. Drechsler, A. Dolganiuc, O. Norkina, L. Romics, W. Li, K. Kodys, F. H. Bach, P. Mandrekar, and G. Szabo
Heme Oxygenase-1 Mediates the Anti-Inflammatory Effects of Acute Alcohol on IL-10 Induction Involving p38 MAPK Activation in Monocytes
J. Immunol., August 15, 2006; 177(4): 2592 - 2600.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. Gong and A. I. Cederbaum
Transcription Factor Nrf2 Protects HepG2 Cells against CYP2E1 plus Arachidonic Acid-dependent Toxicity
J. Biol. Chem., May 26, 2006; 281(21): 14573 - 14579.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
S. W. Ryter, J. Alam, and A. M. K. Choi
Heme Oxygenase-1/Carbon Monoxide: From Basic Science to Therapeutic Applications
Physiol Rev, April 1, 2006; 86(2): 583 - 650.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
D. Wu and A. I. Cederbaum
Opposite action of S-adenosyl methionine and its metabolites on CYP2E1-mediated toxicity in pyrazole-induced rat hepatocytes and HepG2 E47 cells
Am J Physiol Gastrointest Liver Physiol, April 1, 2006; 290(4): G674 - G684.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
P.-H. Park, R. W. Lim, and S. D. Shukla
Involvement of histone acetyltransferase (HAT) in ethanol-induced acetylation of histone H3 in hepatocytes: potential mechanism for gene expression
Am J Physiol Gastrointest Liver Physiol, December 1, 2005; 289(6): G1124 - G1136.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
L. A.B. Joosten, R. L. Smeets, M. I. Koenders, L. A.M. van den Bersselaar, M. M.A. Helsen, B. Oppers-Walgreen, E. Lubberts, Y. Iwakura, F. A.J. van de Loo, and W. B. van den Berg
Interleukin-18 Promotes Joint Inflammation and Induces Interleukin-1-Driven Cartilage Destruction
Am. J. Pathol., September 1, 2004; 165(3): 959 - 967.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Alvarez-Maqueda, R. E. Bekay, G. Alba, J. Monteseirin, P. Chacon, A. Vega, J. Martin-Nieto, F. J. Bedoya, E. Pintado, and F. Sobrino
15-Deoxy-{Delta}12,14-prostaglandin J2 Induces Heme Oxygenase-1 Gene Expression in a Reactive Oxygen Species-dependent Manner in Human Lymphocytes
J. Biol. Chem., May 21, 2004; 279(21): 21929 - 21937.
[Abstract] [Full Text] [PDF]